Hyloris Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Hyloris Pharmaceuticals has a total shareholder equity of €39.1M and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €47.7M and €8.6M respectively.
Key information
0%
Debt to equity ratio
€0
Debt
Interest coverage ratio | n/a |
Cash | €30.91m |
Equity | €39.07m |
Total liabilities | €8.61m |
Total assets | €47.68m |
Financial Position Analysis
Short Term Liabilities: HYL's short term assets (€35.3M) exceed its short term liabilities (€6.8M).
Long Term Liabilities: HYL's short term assets (€35.3M) exceed its long term liabilities (€1.9M).
Debt to Equity History and Analysis
Debt Level: HYL is debt free.
Reducing Debt: HYL currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HYL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HYL has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 18.8% each year.